Gil Beyen, Erytech CEO
April 26, 2022 10:38 AM EDT
Manufacturing

Catal­ent stays hot as it inks deal with French phar­ma that suf­fered PhI­II flop

Josh Sullivan

Just a cou­ple of deals in a cou­ple of days for Catal­ent.

The New Jer­sey-based CD­MO’s lat­est move is a long-term sup­ply

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times